BioSpace News Archive

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the fourth-quarter and full-year 2021.

PolyPid Ltd. announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2021, and recent business highlights.

Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today announced that it has entered into a license agreement with East Carolina University.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that members of management will present at the following investor conferences.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that the Company has completed its spinoff of ZimVie, Zimmer Biomet’s former Dental and Spine business.

Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced financial results for the fourth quarter and fiscal year ended December 31, 2021.

Visby Medical™, a leading medical diagnostic company, announced that it has raised over $100 million in its Series E financing round, with investment led by Ping An Voyager Partners and joined by the Healthcare of Ontario Pension Plan.

Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, taking place March 18-21, 2022.

LumiraDx Limited announced that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx $56.5 million aggregate principal amount of 6.00% Convertible Senior Subordinated Notes due 2027.